\n<\/p>\n
– Listing on the new “Sparks”
\nsegment of SIX Swiss Exchange for small and medium-sized companies is planned
\nfor Q1 2022, subject to market environment<\/i><\/p>\n
– Xlife Sciences AG is a Swiss company focused
\non the value development and commercialization of promising research projects
\nfrom universities and other research institutions in the field of life sciences<\/i><\/p>\n
– The company is involved as incubator and
\naccelerator in in 23 project companies until the successful exit after the
\nproof-of-concept phase with the goal of participating in their <\/i>
\nlong-term value development<\/i><\/p>\n
– Xlife Sciences is currently listed on the
\nMunich Stock Exchange and has a market capitalization of EUR 233 million as per
\nend of 2021.<\/i><\/p>\n
Dr. Bernhard Scholz, Chairman of the Board of Xlife Sciences, comments:
Oliver R. Baumann, CEO of Xlife Sciences, added: “With the planned
The Company<\/b> Xlife Sciences brings carefully selected early-stage projects in the four
The team of Xlife Sciences has proven experience in the life sciences sector
Currently, the portfolio of Xlife Sciences comprises 23 project companies.
Planned listing on SIX Swiss Exchange<\/b> Following the intended listing on SIX Swiss Exchange, the proportion of
Since October 1, 2021, fast-growing, small and medium-sized enterprises
– Listing on the new “Sparks”
segment of SIX Swiss Exchange for small and medium-sized companies is planned
for Q1 2022, subject to market environment – Xlife Sciences AG is a Swiss company focused
on the value development and commercialization of promising research projects
from universities and other research institutions in the field of life …<\/p>\n","protected":false},"author":1,"featured_media":19834,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[60],"tags":[],"_links":{"self":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/19833"}],"collection":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/comments?post=19833"}],"version-history":[{"count":0,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/19833\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media\/19834"}],"wp:attachment":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media?parent=19833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/categories?post=19833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/tags?post=19833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nZURICH,
\nSWITZERLAND – EQS Newswire – 10 January 2022 –\u00a0Xlife
\nSciences AG<\/a> (XLS DE) confirms its intention to be listed on SIX Swiss Exchange,
\nas communicated in November 2021. Subject to market environment, the listing on
\nthe new “Sparks” segment of SIX Swiss Exchange is still planned for
\nQ1 2022.<\/p>\n
\n“Switzerland has a strong and dynamic life sciences industry and
\ncorrespondingly knowledgeable investors and analysts. The new Sparks segment of
\nthe Swiss stock exchange is attractive for Xlife Sciences as an emerging growth
\ncompany and should further increase our visibility and market
\ntransparency.”<\/p>\n
\nlisting in Switzerland and the accompanying move to a regulated market, we aim
\nto make our company more accessible to institutional investors, increase the
\nliquidity of the stock and further enhance the transparency of Xlife
\nSciences.”<\/p>\n
\nXlife Sciences is a Swiss company focused on the value development and
\ncommercialization of promising research projects from universities and other
\nresearch institutions in the field of life sciences. The goal is to bridge the
\ngap from research and development to healthcare markets.<\/p>\n
\nareas of technological platforms, biotechnology\/therapies, medical technology,
\nand artificial intelligence\/digital health to the next stage of development.
\nThe focus is on preclinical projects in biotechnology that are acquired with a
\nsuccessful spin-off by a university, a clinical center, or a research
\ninstitution. Currently, eleven employees and eight consultants work for Xlife
\nSciences AG; across all project companies, there are more than 120 scientific
\nemployees, researchers, and project managers in total.<\/p>\n
\nthanks to the many years of expertise in successful partnering of the company
\nfounders and the scientific advisory board. In addition to Chairman Dr.
\nBernhard Scholz, the Board of Directors comprises Christian Faber, Prof. Dr.
\nhabil. Michael B. Klein, Mark S. M\u00fcller, and Simon Sch\u00f6ni. The Management Team
\nconsists of CEO Oliver R. Baumann (also member of the Board of Directors), CFO
\nCarl von Halem, Chief Scientific Officer (CSO) Frank Pl\u00f6ger, and Beat Kl\u00e4ui as
\nHead of Accounting & Taxation.<\/p>\n
\nThe Value Chain<\/b>
\nXlife Sciences generally focuses its involvement in a project on the early
\nphase, i.e., until completion of the so-called “proof-of-concept”
\nphase, and subsequently strives to commercialize the project company, e.g.,
\nthrough a sale of the company or individual product candidates (“trade
\nsale”), through out-licensing of products or patents, or through an IPO of
\nthe project company. This strategy enables Xlife Sciences to realize an
\nincrease in value already after the proof-of-concept phase. Potential future
\ngrowth opportunities are also captured with possible milestone payments and
\nroyalties in the later market phase.<\/p>\n
\nThe Project Companies<\/b>
\nXlife Sciences cooperates with 15 prominent universities and research
\ninstitutes from Germany and Switzerland, and reviews invention disclosures and
\nproject ideas in a thorough and structured three-step due-diligence process. If
\nXlife Sciences decides to take over the invention disclosure, usually a
\nseparate project company is founded for this purpose and prepared for the
\npossible exit after a successful proof-of-concept phase (2-3 years). In
\naddition, these companies are supported in positioning, structuring, and
\nimplementing their concepts, for example by providing management services.
\nFurthermore, Xlife Sciences aims to create and exploit synergies between the
\nproject companies.<\/p>\n
\nFive project companies are based in Switzerland, the others mostly in Germany.
\nAccording to the current assessment of the Management Team, the project
\ncompanies Veraxa Biotech, Laxxon Medical, Lysatpharma, Quadira Biosciences,
\nSaniva, Vitruvia, Synimmune, Ix Therapeutics, and Baliopharm are among the
\nshort- and medium-term growth drivers of Xlife Sciences. These growth drivers
\ncan be, for example, an exit, the completion of the preclinical development
\nphase, further commitments of federal funds or even the first-time revenue
\ngeneration.<\/p>\n
\nCurrently, the company is admitted to trading on the Munich Stock Exchange
\n(unregulated market [“Freiverkehr”] in the segment m:access) with a
\nmarket capitalization of EUR 233 million as of the end of 2021. Concurrently
\nwith the listing on SIX Swiss Exchange on the new “Sparks” segment,
\ntrading of the shares of Xlife Sciences AG on the Munich Stock Exchange shall
\nbe ceased for regulatory reasons. The shares will be tradeable on SIX Swiss
\nExchange after the switch to SIX Swiss Exchange.<\/p>\n
\nfreely tradable shares (“free float”) is expected remain at
\napproximately 44%, the current quota on the Munich Stock Exchange. The majority
\nof the shares will continue to be held by the two founders as well as the
\nmembers of the Board of Directors and management team.<\/p>\n
\n(SMEs) have been able to list on the “Sparks” segment of SIX Swiss
\nExchange. This is a regulated trading segment tailored to the requirements of
\nSMEs and their investors. Among other things, the segment provides for easier
\naccess for younger companies and a condensed trading window. Apart from that,
\nSMEs are subject to the same prospectus requirements, the same regulatory
\noversight and the same reporting requirements as companies traded on the main
\nsegment of SIX Swiss Exchange.<\/p>\n<\/p><\/div>\n\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"